Brief communication: immunogenicity of measles vaccine when co-administered with 10-valent pneumococcal conjugate vaccine
Zheng Quan Toh, Beth Temple, Tran Ngoc Huu, Vo Thi Trang Dai, Nguyen Trong Toan, Doan Y Uyen, Kathryn Bright, Lien Anh Ha Do, E Kim Mulholland, Paul V Licciardi
NPJ VACCINES | NATURE RESEARCH | Published : 2020
This brief communication describes the findings from a randomised controlled trial in Vietnam that co-administration of measles vaccine (MV) with 10-valent pneumococcal conjugate vaccine (PCV10, Synflorix®, GSK) does not affect the immunogenicity of MV. These findings are most relevant for low- and middle-income countries (LMICs) in Asia considering PCV introduction.
Related Projects (1)
Awarded by National Health and Medical Research Council of Australia
Awarded by Bill & Melinda Gates Foundation
We thank the study participants and their families. We also thank Laboratory Services at the Royal Children's Hospital, Parkville, Australia for performing the measles immunogenicity testing. This work was supported by the National Health and Medical Research Council of Australia (grant number 566792) and the Bill & Melinda Gates Foundation (grant number OPP1116833). GlaxoSmithKline Biologicals SA donated the doses of PCV10.